CC-90011 + carboplatin + etoposide + nivolumab

**CC-90011 + carboplatin + etoposide + nivolumab** is an investigational combination therapy studied in subjects with extensive-stage small cell lung cancer (ES-SCLC). CC-90011 is a potent, oral, selective, reversible inhibitor of lysine-specific demethylase 1 (LSD1), an epigenetic modulator implicated in oncogenesis and tumor cell differentiation[1][3]. Carboplatin and etoposide are standard cytotoxic chemotherapy agents: carboplatin is a platinum-based DNA crosslinker and etoposide is a topoisomerase II inhibitor. Nivolumab is a monoclonal antibody immune checkpoint inhibitor targeting programmed death-1 (PD-1), promoting T-cell mediated antitumor immunity. The combination leverages targeted epigenetic modulation (CC-90011), DNA damage (carboplatin, etoposide), and immune checkpoint blockade (nivolumab) for synergistic anti-cancer effects[2][6][4].